Safety Profile of the Viral Vectors of Attenuated Fowlpox Strain FP9 and Modified Vaccinia Virus Ankara Recombinant for Either of 2 Preerythrocytic Malaria Antigens, ME-TRAP or the Circumsporozoite Protein, in Children and Adults in Kenya | Zendy

Philip Bejon | Zendy; N. Peshu | Zendy; Sarah C. Gilbert | Zendy; Brett Lowe | Zendy; Sassy Molyneux | Zendy; J. Forsdyke | Zendy; Trudie Lang | Zendy; Adrian V. S. Hill | Zendy; Kevin Marsh | Zendy

Open Access

Safety Profile of the Viral Vectors of Attenuated Fowlpox Strain FP9 and Modified Vaccinia Virus Ankara Recombinant for Either of 2 Preerythrocytic Malaria Antigens, ME-TRAP or the Circumsporozoite Protein, in Children and Adults in Kenya

Author(s) -

Philip Bejon,

N. Peshu,

Sarah C. Gilbert,

Brett Lowe,

Sassy Molyneux,

J. Forsdyke,

Trudie Lang,

Adrian V. S. Hill,

Kevin Marsh

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/501459

Subject(s) - reactogenicity , virology , circumsporozoite protein , vaccinia , modified vaccinia ankara , medicine , malaria vaccine , vaccination , malaria , immunization , immunology , antigen , biology , plasmodium falciparum , recombinant dna , biochemistry , gene

We are developing a heterologous prime-boost vaccine strategy against malaria. This approach uses sequential immunization with different vectors to deliver a common preerythrocytic malaria antigen. Preliminary evidence of efficacy and safety has been previously documented in studies from an area where malaria is nonendemic. Additional safety data from an area where malaria is endemic are now required before larger-scale studies are undertaken to determine the efficacy of this vaccine strategy in the field. Other modified vaccinia virus Ankara (MVA) recombinants and prime-boost immunizations are being developed as vaccines against human immunodeficiency virus (HIV) infection, tuberculosis, and cancer, and MVA is a candidate attenuated smallpox vaccine.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research